✦ LIBER ✦
To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress
✍ Scribed by Costa, Daniel B.
- Book ID
- 119319662
- Publisher
- Elsevier Science
- Year
- 2007
- Tongue
- English
- Weight
- 103 KB
- Volume
- 57
- Category
- Article
- ISSN
- 0169-5002
No coin nor oath required. For personal study only.